Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05862012Phase 1Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Role: lead

NCT05427812Phase 1Terminated

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Role: lead

NCT03309111Phase 1Completed

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Role: lead

NCT03568162Phase 2Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Role: lead

NCT03983395Phase 1Terminated

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Role: lead

NCT02829372Phase 1Terminated

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

Role: lead

NCT02683928Phase 2Completed

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

Role: lead

All 7 trials loaded